The 57% dilution from this overnight offering is a clear negative signal — expect significant downward pressure on EDIT shares on the open following this pricing, likely toward or below the $2.25 offering price. Existing holders are being severely diluted. Monitor for further downside if the broader market reads this as a sign of desperate capital needs given the pre-revenue stage and the early nature of the EDIT-401 program. Warrants at $3.50 (27% above the offering price) provide an additional overhang.
Price Chart
Executive Summary
Editas Medicine is issuing 55,555,556 shares of common stock and accompanying warrants in a $125M underwritten public offering at a combined price of $2.25 per unit, priced at a ~18.5% discount to the last closing price of $2.76. The net proceeds of ~$117M will fund clinical development of lead candidate EDIT-401 and for working capital. This is a highly dilutive offering — increasing shares outstanding by ~57% — and represents a material near-term bearish catalyst for the stock.
Key Facts
- 55,555,556 shares of common stock + 55,555,556 warrants offered at $2.25/unit for total gross proceeds of $125M
- Net proceeds estimated at ~$117M after underwriting discounts and commissions and expenses
- Stock closed at $2.76 on May 22, 2026 — offering priced at an ~18.5% discount
- Pre-money shares outstanding: 97,906,282 (April 30, 2026). Post-offering: 153,461,838 — a 56.8% increase in share count
- Warrants exercisable at $3.50/share, expire on earlier of positive EDIT-401 Phase 1 data announcement + 30 days, or 3 years from issuance
- Existing cash and equivalents were $123.6M as of March 31, 2026; post-offering cash runway extended into H2 2028
- Stock price immediately before offering was $2.76; offering priced at 18.5% below market
- Current market cap ~$270M; offering size equals ~46% of pre-offering market cap
Financial Impact
$125M gross / ~$117M net proceeds raised; 56.8% increase in outstanding shares; immediate dilution of $1.46 per share to new investors
Risk Factors
- Massive dilution — 57% increase in share count will pressure the stock
- Offering priced at a steep ~18.5% discount to the prior close, signaling weak demand
- As a pre-revenue biotech with a market cap of only ~$270M, raising $125M (46% of market cap) is an outsized financing event
- Warrants to purchase another 55.6M shares at $3.50 create further overhang
- No guarantee of successful clinical development for EDIT-401, the sole value-driver for the stock
- Cantor and Wells Fargo as underwriters — underwriter comp model includes ongoing 1% fee on warrant exercises
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-066382 |
| Document: 0001104659-26-066382-index-headers.html | 0001104659-26-066382 |
| Document: 0001104659-26-066382-index.html | 0001104659-26-066382 |
| Document: 0001104659-26-066382.txt | 0001104659-26-066382 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 8-K | $2.84 | awaiting T+20 | — | $2.40 (−15.49%) |
Sep 9, 2026 6w ago | EFFECT | $2.77 $2.75 | ▼ −0.72% | ▼ −2.92% | $2.40 (−13.36%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.44 $3.30 | ▲ +35.25% | ▲ +33.35% | $2.40 (−1.64%) |
May 26, 2026 21w ago | 424B5 | $3.57 $2.74 | ▲ +23.25% | ▲ +21.35% | $2.40 (+32.77%) |
May 26, 2026 21w ago | 8-K | $3.57 $2.74 | ▲ +23.25% | ▲ +21.35% | $2.40 (+32.77%) |
May 26, 2026 21w ago | Press Release | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 21w ago | 8-K | $3.08 $2.83 | ▼ −8.12% | ▼ −6.17% | $2.40 (−22.08%) |
May 26, 2026 21w ago | 424B5 | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 21w ago | Press Release | $3.08 $2.83 | ▲ +8.12% | ▲ +6.17% | $2.40 (+22.08%) |
May 26, 2026 21w ago | Press Release | $3.08 $2.83 | ▼ −8.12% | ▼ −6.17% | $2.40 (−22.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers